Homeโ€บArticlesโ€บThe isoxazoline four brothers: a chasm in adverse-event reporting volume

The isoxazoline four brothers: a chasm in adverse-event reporting volume

Four veterinary ectoparasiticides share the same chemical scaffold and the same mode of action. Afoxolaner (้˜ฟ็ฆๆ‹‰็บณ), fluralaner (ๆฐŸ้›ทๆ‹‰็บณ), sarolaner (ๆฒ™็ฝ—ๆ‹‰็บณ) and lotilaner (ๆด›ๆ›ฟๆ‹‰็บณ) are all isoxazoline-class agents โ€” they block insect and acarine GABA- and glutamate-gated chloride channels, killing fleas and ticks. In the United States they are all captured in the FDA Center for Veterinary Medicine's adverse-event database, exposed through the openFDA animalandveterinary/event.json endpoint. They are, in a very real sense, four brothers from one chemical family.

And yet when you line up their adverse-event (ADE) report counts, the four brothers are not standing shoulder to shoulder. Two of them carry report volumes near or above 80,000; one sits just under 70,000; and the youngest trails by an order of magnitude. This article is the sister piece to the fluralaner deep-dive โ€” here we widen the lens to all four and ask a deceptively simple question: why does the same class show such a chasm in reporting volume, when their market footprint is, on paper, far more even?

The headline numbers

All figures below are cumulative FDA animal-and-veterinary adverse-event report totals, pulled from openFDA at the snapshot dated 2026-07-21 / 2026-07-22 (the source topics were pulled on both dates and carry identical totals). The four brothers, ranked by total reports:

  • Fluralaner (ๆฐŸ้›ทๆ‹‰็บณ): 88486
  • Sarolaner (ๆฒ™็ฝ—ๆ‹‰็บณ): 79692
  • Afoxolaner (้˜ฟ็ฆๆ‹‰็บณ): 69037
  • Lotilaner (ๆด›ๆ›ฟๆ‹‰็บณ): 13432

Read plainly: fluralaner and sarolaner occupy the 80kโ€“89k band; afoxolaner is a close third at just under 70k; and lotilaner sits far below at roughly 13k โ€” about one-fifth of afoxolaner's total and one-seventh of fluralaner's.

Critical disclaimer โ€” read before interpreting any number above. Every count in this article is cumulative as of the openFDA pull snapshot 2026-07-21 / 2026-07-22. A report being filed in the FDA CVM database does not establish that the drug caused the event: reported โ‰  causal. These are spontaneous, passive-surveillance reports submitted by veterinarians, pet owners, and manufacturers; they are not controlled studies and carry no causal attribution. Furthermore, under the VEDDRA coding scheme used here, "Lack of efficacy" terms denote product-performance reports (the product didn't kill the parasite), not adverse reactions in the animal. They are reported separately and must not be read as toxicity.

A chasm against market breadth

The obvious hypothesis is that report volume tracks market size: the more animals treated, the more reports filed. If that were the whole story, lotilaner's low count would simply mean a smaller market. But the available market-authorization data complicates the tidy version of that story.

Species breadth โ€” where the reports actually land

The dog counts show all four brothers are overwhelmingly canine products, but with different shapes:

  • Fluralaner: Dog 65708 of 88486
  • Sarolaner: Dog 67742 of 79692
  • Afoxolaner: Dog 63981 of 69037
  • Lotilaner: Dog 11534 of 13432

Now look at the cat signal โ€” the clearest breadth marker in the set:

  • Fluralaner: Cat 13343
  • Sarolaner: Cat 8207
  • Lotilaner: Cat 859
  • Afoxolaner: Cat 82

Fluralaner's 13343 cat reports are roughly 15% of its entire total โ€” a substantial multi-species companion-animal footprint. Sarolaner, too, shows meaningful cat exposure (8207). By contrast, afoxolaner reports are almost purely canine (82 cat of 69037), and lotilaner's cat count (859) is a small slice of a small total.

Human exposure reports widen the picture further: fluralaner carries 1288 human reports, sarolaner 143, afoxolaner 92, lotilaner 27. Fluralaner additionally records Rabbit 6, Fox 3, Goat 3; sarolaner Rabbit 3, Bobcat 2, Lynx 2; afoxolaner Other 3, Other Canids 3; lotilaner Cattle 1, Pig 1. The breadth of species touched is itself uneven across the brothers.

Market-authorization breadth on the record

From the approval-label topics available in the source set, two of the four brothers have a first-hand Canadian market-authorization record on file:

  • NEXGARD (afoxolaner, ้˜ฟ็ฆๆ‹‰็บณ) โ€” Marketed in Canada, DIN 02427435, BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC., species Dogs, PRESCRIPTION, active AFOXOLANER 11.3 MG, therapeutic class ectoparasiticide (oral).
  • SIMPARICA (sarolaner, ๆฒ™็ฝ—ๆ‹‰็บณ) โ€” Marketed in Canada, DIN 02452014, ZOETIS CANADA INC, species Dogs, PRESCRIPTION, active SAROLANER 5 MG, therapeutic class ectoparasiticide (oral).

A note of honesty: approval-label topics for fluralaner and lotilaner products were not present in the source material used here. So any breadth claim about those two rests on the ADE species signal above, not on a registration record in this dataset. We do not fill the gap with assumption.

What's actually being reported

Stripping out the "lack of efficacy" product-performance reports, the clinical reaction profile is dominated by gastrointestinal and neurological terms across all four. Verbatim top VEDDRA terms from the source topics:

  • Afoxolaner: Vomiting 15987, Diarrhoea 6128, Lethargy (see also Central nervous system depression in 'Neurological') 5710, Lack of efficacy (ectoparasite) - tick NOS 4991, Lack of efficacy (ectoparasite) - flea 4532, Seizure NOS 4406.
  • Fluralaner: Vomiting 20360, Lack of efficacy (ectoparasite) - flea 17108, Emesis (multiple) 6345, Lethargy (see also Central nervous system depression in 'Neurological') 6117, Lack of efficacy (ectoparasite) - tick NOS 5244, Diarrhoea 4741, UNPALATABLE 4069, Seizure NOS 3347, Application site hair loss 2487, Product Defect, General 2323.
  • Sarolaner: Vomiting 13516, Seizure NOS 7249, Lack of efficacy (bacteria) - Borrelia 6736, Lack of efficacy (endoparasite) - heartworm 6178, Diarrhoea 5497, Lack of efficacy (endoparasite) - hookworm 4379, Lack of efficacy (ectoparasite) - tick NOS 4305, Lethargy (see also Central nervous system depression in 'Neurological') 4241, Lack of efficacy (endoparasite) - roundworm NOS 3464, Lack of efficacy (ectoparasite) - flea 3404.
  • Lotilaner: Vomiting 3355, Diarrhoea 1586, UNPALATABLE 906, Other abnormal test result NOS 848, Lack of efficacy (ectoparasite) - tick NOS 759, Seizure NOS 729, Lack of efficacy (bacteria) - Borrelia 707, Lethargy (see also Central nervous system depression in 'Neurological') 667, Lack of efficacy (ectoparasite) - flea 637.

Two things stand out. First, Seizure NOS appears in every brother: 4406 (afoxolaner), 3347 (fluralaner), 7249 (sarolaner), 729 (lotilaner). The neurological signal is class-wide, not unique to one molecule. Second, sarolaner's top clinical reaction is Seizure NOS (7249) โ€” the highest seizure count of the four โ€” while fluralaner's headline is lifted by a massive Lack of efficacy (ectoparasite) - flea 17108, a product-performance term that is not an adverse reaction.

The four in the dog landscape

Zooming out to the whole canine adverse-event universe, the ade_top_actives_dog topic reports 985705 total Dog ADE reports. The isoxazolines appear inside the upper ranks of that list:

  • Pyrantel Pamoate;Sarolaner 50473
  • Afoxolaner 49881
  • Fluralaner Chew Tablets 32050
  • Fluralaner 13.64% 12-Week Chew 26255

For scale, the very top of the dog list is Spinosad 180156, Milbemycin Oxime 168422, Ivermectin 103618, Pyrantel As Pamoate Salt 82225, Moxidectin 59458. Fluralaner is split across two distinct product-name entries (Chew Tablets and the 13.64% 12-Week Chew), which is itself a reminder that the ingredient-level totals in the first section are not directly comparable to the product-level rows here โ€” combo and branded forms fragment the same molecule.

Why the chasm, then?

The data on disk does not let us prove a cause for the volume gap โ€” and per the disclaimer, it was never designed to. But it does let us reject the laziest explanation. Report volume is not a clean proxy for either intrinsic danger or for simple market share: lotilaner's low total coincides with a narrow species footprint (mostly dogs, 11534 of 13432, with only 859 cat and 27 human), while fluralaner's high total rides on the broadest species spread of the four (13343 cat, 1288 human, plus rabbit/fox/goat). Sarolaner's 79692 is buoyed by strong dog and cat numbers and a notably high seizure count. Afoxolaner, though third in volume, is almost purely canine in its reporting.

In other words, the "chasm" is partly a chasm of exposure surface โ€” how many species, how many markets, how many combination products โ€” rather than a chasm of per-animal risk. That is precisely the kind of nuance a raw ranking hides, and the reason this series treats each molecule on its own terms before drawing any cross-class conclusion.

Disclaimer and methodology

  • All ADE counts are cumulative as of the openFDA pull snapshot 2026-07-21 / 2026-07-22 (source topics pulled on both dates with identical totals). Counts are report-level: one report may list multiple reactions and multiple animals, so figures are not additive.
  • Reported โ‰  causal. FDA CVM adverse-event reports are spontaneous passive-surveillance submissions and establish no causation.
  • Under VEDDRA, "Lack of efficacy" terms denote product-performance reports and are not adverse reactions; they are reported separately.
  • Approval-label breadth is limited in this article to the two registration records present in the source set (NEXGARD / afoxolaner; SIMPARICA / sarolaner). Fluralaner and lotilaner product labels were not in the available sources and are not asserted.
  • Every number in this article is a verbatim substring of the listed source topics.

Sources

  • ade_afoxolaner_adverse_events โ€” Afoxolaner total 69037; Dog 63981, Cat 82, Human 92, Other 3, Other Canids 3; top reactions Vomiting 15987, Diarrhoea 6128, Lethargy 5710, Seizure NOS 4406, etc. (openFDA animalandveterinary/event.json, pulled 2026-07-21 / 2026-07-22)
  • ade_fluralaner_adverse_events โ€” Fluralaner total 88486; Dog 65708, Cat 13343, Human 1288, Rabbit 6, Fox 3, Goat 3; top reactions Vomiting 20360, Lack of efficacy (ectoparasite) - flea 17108, Seizure NOS 3347, etc.
  • ade_sarolaner_adverse_events โ€” Sarolaner total 79692; Dog 67742, Cat 8207, Human 143, Rabbit 3, Bobcat 2, Lynx 2; top reactions Vomiting 13516, Seizure NOS 7249, Lack of efficacy heartworm 6178, etc.
  • ade_lotilaner_adverse_events โ€” Lotilaner total 13432; Dog 11534, Cat 859, Human 27, Cattle 1, Pig 1; top reactions Vomiting 3355, Diarrhoea 1586, Seizure NOS 729, etc.
  • ade_top_actives_dog โ€” total Dog ADE reports 985705; Afoxolaner 49881, Pyrantel Pamoate;Sarolaner 50473, Fluralaner Chew Tablets 32050, Fluralaner 13.64% 12-Week Chew 26255; leaders Spinosad 180156, Milbemycin Oxime 168422, Ivermectin 103618.
  • approval_label_nexgard โ€” NEXGARD (afoxolaner) Marketed, DIN 02427435, BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC., Dogs, PRESCRIPTION, AFOXOLANER 11.3 MG, ectoparasiticide (oral). Health Canada DPD.
  • approval_label_simparica โ€” SIMPARICA (sarolaner) Marketed, DIN 02452014, ZOETIS CANADA INC, Dogs, PRESCRIPTION, SAROLANER 5 MG, ectoparasiticide (oral). Health Canada DPD.

Authored by codebuddy ยท Compiled from 7 verified Pet Data Station topics (sources available on request).